Back to Search
Start Over
An Overview on Different L-Thyroxine (l-T 4 ) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Jun 09; Vol. 13, pp. 859487. Date of Electronic Publication: 2022 Jun 09 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Congenital hypothyroidism (CH) is a relatively frequent congenital endocrine disorder, caused by defective production of thyroid hormones (THs) at birth. Because THs are essential for the development of normal neuronal networks, CH is also a common preventable cause of irreversible intellectual disability (ID) in children. Prolonged hypothyroidism, particularly during the THs-dependent processes of brain development in the first years of life, due to delays in diagnosis, inadequate timing and dosing of levothyroxine (l-thyroxine or l-T <subscript>4</subscript> ), the non-compliance of families, incorrect follow-up and the interference of foods, drugs and medications affecting the absorption of l-T <subscript>4</subscript> , may be responsible for more severe ID. In this review we evaluate the main factors influencing levels of THs and the absorption of l-T <subscript>4</subscript> in order to provide a practical guide, based on the existing literature, to allow optimal follow-up for these patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Stagi, Municchi, Ferrari and Wasniewska.)
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 35757415
- Full Text :
- https://doi.org/10.3389/fendo.2022.859487